Androgens and Anabolic Steroids

Key Points

• Androgens (for example testosterone) replace deficient endogenous hormone in hypogonadism and delayed puberty pathways.
• Anabolic steroids (for example oxandrolone) are used in selected catabolic/wasting conditions to promote tissue rebuilding and weight gain.
• Testosterone is available in oral, injectable, transdermal, buccal, and implantable forms; dosing is formulation-specific.
• Major risks include cardiovascular/hepatic adverse effects, virilization effects, and misuse for bodybuilding/performance enhancement.
• In prepubertal clients, androgen exposure can accelerate bone maturation and prematurely close epiphyseal growth plates.
• Oxandrolone has high-priority liver and lipid-risk warnings and is a DEA Schedule III controlled substance.
• In masculinizing transgender regimens, testosterone targets are typically maintained in a male physiologic range and require structured follow-up monitoring.

Drug Class Overview

Androgens are natural or synthetic testosterone-pathway drugs that bind androgen receptors and support development/maintenance of male sexual characteristics, anabolic metabolism, and erythropoiesis. They are used in clinically confirmed androgen-deficiency states and selected oncology contexts.

Anabolic steroids are testosterone analogs designed to increase protein synthesis and support tissue rebuilding in severe catabolic illness, trauma, long-term corticosteroid exposure, or postoperative recovery pathways.

Common Agents and Typical Dosing

Class	Drug	Typical Adult Dose Range
Androgen	Testosterone (IM or transdermal pathways)	50-400 mg IM every 2-4 weeks, or transdermal 4 mg/day adjusted to serum levels
Androgen	Fluoxymesterone	5-20 mg PO daily for hypogonadism/delayed puberty pathways
Androgen	Methyltestosterone	10-50 mg PO daily for hypogonadism/delayed puberty pathways
Anabolic steroid	Oxandrolone	2.5-20 mg/day PO in 2-4 divided doses

Adverse Effects and Contraindications

Androgen adverse-effect patterns:

• Gynecomastia, acne, edema, mood or libido changes, prolonged erections/priapism risk
• Liver dysfunction signals (including cholestatic jaundice)
• Hypercalcemia risk in immobilized clients
• Virilization effects in female clients (voice deepening, hirsutism, clitoral enlargement, menstrual irregularity)

Anabolic steroid adverse-effect patterns:

• Electrolyte retention/imbalance, edema, lipid worsening, hypertension
• Hepatic injury (including rare necrosis), insomnia, anxiety/depression/aggression
• Male gonadal suppression/testicular atrophy and libido changes
• Female virilization and potential fetal masculinization if exposed during pregnancy

Major contraindication trends:

• Pregnancy/lactation pathways
• Known prostate or male breast cancer
• Severe cardiac, hepatic, or renal disease
• Hypercalcemia or nephrosis contexts (agent-specific)

Oxandrolone Black Box Context

Oxandrolone can cause serious hepatic injury and adverse serum-lipid shifts that increase coronary-risk burden. In children, accelerated bone maturation may reduce final adult height.

Nursing Assessment and Monitoring

• Confirm indication and screen for misuse/nonmedical goals before therapy starts.
• Assess cardiovascular, hepatic, renal, oncologic, and pregnancy/lactation history.
• Obtain baseline and follow-up labs as ordered: CBC, liver/renal function, serum chemistries, and lipid profile.
• Track blood pressure, weight, height, and mood/behavior changes.
• In clients with diabetes using androgen therapy, monitor for glucose-lowering effects and coordinate potential antihyperglycemic dose adjustments.
• In prepubertal therapy pathways, coordinate long-bone radiographs about every 6 months to monitor epiphyseal maturation.
• Monitor for BPH/prostate-symptom worsening and urinary-obstruction cues in older male clients.

Patient Education

• Take medication exactly as prescribed; do not self-adjust or abruptly stop therapy.
• Report chest pain, dyspnea, severe mood change, persistent erection, jaundice, or edema promptly.
• Avoid smoking and alcohol use while on therapy due to additive cardiovascular/hepatic risk.
• Keep follow-up appointments for laboratory and growth monitoring.
• Do not use androgens/anabolic steroids for bodybuilding or athletic performance enhancement.

Related Concepts

• oncologic-hormonal-therapy - Antiandrogen pathways in advanced prostate-cancer treatment.
• gonadotropin-releasing-hormone-gnrh-analogs - Combined androgen-deprivation pathways in metastatic prostate cancer.
• masculinizing-hormonal-therapy - Regimen-level monitoring targets and transgender-focused counseling priorities.
• controlled-substances-and-drug-schedules - Schedule III controlled-substance handling and diversion prevention.
• benign-prostatic-hyperplasia - Testosterone pathways can worsen lower-urinary-tract symptoms in susceptible clients.
• prostate-cancer - Baseline and interval prostate-risk evaluation in androgen-exposed male clients.

Self-Check

1. Which baseline assessments are most important before starting testosterone replacement in an older client?
2. Why are long-bone radiographs required during androgen therapy in prepubertal clients?
3. Which oxandrolone adverse-effect clusters require urgent escalation?